Current approaches to adjuvant therapy of melanoma

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Aamdal, Steinar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CANVAXIN; DACARBAZINE; LEVAMISOLE; PEGINTERFERON ALPHA2B;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; MELANOMA; META-ANALYSIS AS TOPIC; SKIN NEOPLASMS;

EID: 80053262080     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70193-9     Document Type: Article

References (13)

1. CM Balch, AC Buzaid, SJ Soong et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 2001 3635 3648 (Pubitemid 32786276)
2. JM Kirkwood, MH Strawderman, MS Ernstoff, TJ Smith, EC Borden, RH Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 l 1996 Jan 7 17 (Pubitemid 26019991)
3. JM Kirkwood, JG Ibrahim, VK Sondak et al. High- and low-dose Interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2458 (Pubitemid 30415832)
4. AMM Eggermont, S Suciu, R MacKie for the EORTC Melanoma Group Post-surgery adjuvant therapy with intermediate doses of interferon alfa-2b versus observation in patients with stage Ilb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 2005 1189 1196 (Pubitemid 41393597)
5. J Hansson, S Aamdal, L Bastholt et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Nordic Melanoma Cooperative Group Lancet Oncol 2 2011 144 152
6. AMM Eggermont, S Suciu, S Santinami for the EORTC Melanoma Group Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126 (Pubitemid 351952257)
7. S Mocellin, S Pasquali, CR Rossi, D Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Nati Cancer Inst 102 2010 493 501
8. AM Eggermont, A Testori, J Marsden et al. Utility of adjuvant systemic therapy in melanoma Ann Oncol 20 2009 30 34
9. A Bottomley, C Coens, S Suciu et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 18 2009 2916 2923
10. S Ziefle, F Egberts, S Heinze et al. Health-related quality of life before and during adjuvant interferon-a treatment for patients with malignant melanoma (DeCOG-Trial) J Immunother 4 2011 403 408
11. MS Mitchell, J Abrams, JA Thompson et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma J Clin Oncol 25 2007 2078 2085 (Pubitemid 46972794)
12. Morton DL. In: Annual Meeting of the Society of Surgical Oncology. Atlanta, GA, USA: 2006. Plenary presentation.
13. AM Eggermont, S Suciu, W Ruka et al. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. 2008 ASCO Annual Meeting Proceedings Part I J Clin Oncol 26 2008 abstract 9004.